| abstract |
The present invention relates to controlled release formulations of dronedarone or pharmaceutically acceptable salts, esters, metabolites, prodrugs or optical isomers thereof and controlled release polymers. The use of a controlled release formulation of dronedarone will improve patient compliance by reducing bioavailability and the number of medications taken per day. [Selection figure] None |